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 ABSTRACT 
     Purpose: The EBV oncoprotein, latent membrane protein 1 (LMP1), contributes 
to the metastasis of nasopharyngeal carcinoma (NPC) by inducing factors to promote 
tumor invasion and angiogenesis. The receptor for advanced glycation endproducts 
(RAGE) is associated with abnormal angiogenesis in diabetic microangiopathies. 
Moreover, some papers have suggested the association of RAGE overexpression with 
tumor metastasis; thus, the associations of RAGE with LMP1 and angiogenesis in NPC 
were examined. 
     Experimental Design: Forty-two patients with NPC were evaluated for 
expressions of LMP1, RAGE, and S100 proteins, and for microvessel counts by 
immunohistochemistry. Then, the RAGE-induction by LMP1 was examined with 
Western blotting and luciferase reporter assay. 
     Results: The microvessel counts were significantly higher in patients with high 
LMP1 expression or high RAGE expression compared to cases with low expressions (P 
= 0.0049 and P <0.0001), respectively. Patients with advanced N classification were 
also significantly increased in these groups (P = 0.0484 and P = 0.0005).  The 
expressions of LMP1 and RAGE proteins were clearly correlated in NPC tissues (P = 
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0.0093). Transient transfection with LMP1 expression plasmid induced RAGE protein 
in Ad-AH cells. The expression of LMP1 transactivated the RAGE promoter as 
demonstrated by luciferase reporter assay. Mutation of the reporter at nuclear factor-κB 
(NF-κB) binding site (-671 to -663) abolished transactivation of the RAGE promoter by 
LMP1. 
     Conclusion: These results suggest that LMP1-induced RAGE enhances lymph 
node metastasis through the induction of angiogenesis in NPC. NF-κB binding site 
(-671 to -663) is essential for transactivation of the RAGE promoter by LMP1. 




     Nasopharyngeal carcinoma (NPC) has invasive and metastatic features, and 
approximately 90 % of patients show cervical lymph node metastasis at the time of 
initial diagnosis (1). As the biological behavior of NPC depends on its nodal status, 
patients with advanced nodal disease have a higher tendency toward a poor outcome. 
Another distinctive character of NPC is the consistent association with Epstein-Barr 
virus (EBV) (2). EBV-encoded latent membrane protein 1 (LMP1) is capable of 
transforming rodent fibroblasts into tumorigenic cells in vitro. (3). Two domains in the 
cytoplasmic carboxyl tail of LMP1, C-terminal-activating regions (CTAR) 1 and 
CTAR2, are essential for the activation of multiple cellular signaling pathways, 
including nuclear factor (NF)-κB, p38/mitogen-activated protein kinase (MAPK), signal 
transducer activators of transcription (STAT), AP-1 and phosphatidylinositol 3 kinase 
(PI3-K) (4). Previously, we reported that LMP1-positive NPCs are more progressive 
with an increased tendency toward lymph node metastasis than LMP1-negative cases (5, 
6). LMP1 is able to directly induce matrix metalloproteinase 9 (MMP9), which plays a 
critical role in invasion of the basement membrane (7). Recently, we reported that 
induction of Twist by LMP1 is directly associated with the metastatic nature of NPC (8). 
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LMP1 also promotes cell migration and invasive growth via Ets-1 expression (9). In 
addition, LMP1 induces and causes the release of fibroblast growth factor 2 (FGF2) into 
extracellular fluid (10). LMP1 also induces vascular endothelial growth factor (VEGF) 
through induction of cyclooxygenase 2 (COX2) and hypoxia-inducible factor 1α 
(HIF-1α) (11, 12). Thus, LMP1 induces a comprehensive set of cellular factors that 
mediate steps in the process of invasion and metastasis of tumor cells as well as 
angiogenesis.    
     The receptor for advanced glycation end products (RAGE) is a multi-ligand 
receptor belonging to the immunoglobulin superfamily (13). It is implicated in 
homeostasis, the development of embryonic neurons, inflammation, and tissue damage 
in diabetes mellitus and Alzheimer’s disease. In addition, RAGE is associated with 
abnormal neovascularization in diabetic retinopathy (14). Furthermore, it has been 
shown that overexpression of RAGE promotes cell survival through increased 
expression of the anti-apoptotic protein bcl-2 (15). Recently, RAGE has been regarded 
as a tumor invasion- and metastasis-related protein (16). Several reports on the 
relationship between RAGE expression and cancer have been published to date (17-21). 
RAGE expression has been reported to be significantly associated with lymph node 
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metastasis in gastric, colorectal, and prostate cancer (18, 20, 21). Major ligands of 
RAGE are S100/calgulanin, amphoterin, advanced glycation end products (AGEs), and 
amyloid-β peptide (22). Among them, S100 molecules are small (9-12 kDa) 
calcium-binding proteins that display 30% to 50% homology within the family. S100 
proteins have recently become of major interest owing to their differential expression in 
a variety of tumors (23).  
     Here, we present a novel view on the mechanism of the high metastatic features 
of NPC: EBV-LMP1 contributes to the metastasis of NPC by induction of RAGE. To 
confirm our view on metastasis, we investigated the expressions of LMP1, RAGE, and 
S100 proteins by immunohistochemical analysis in NPC tissues to assess the 
correlations of these expressions with clinicopathologic parameters. Furthermore, we 
examined the induction of RAGE by LMP1 in nasopharyngeal epithelial cells in vitro. 
Finally, we confirmed the importance of NF-κB in transcriptional activation of RAGE 
promoter by LMP1.  
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MATERIALS AND METHODS 
     Tissue Samples. Forty-two specimens were obtained from patients with NPC 
who underwent biopsy at Kanazawa University Hospital or Toyama Prefectural Central 
Hospital from 1996 to 2006. All specimens were fixed in 10% neutral formalin and 
embedded in paraffin. After a review of all hematoxylin-eosin-stained slides of the 
specimens, they were classified histopathologically on the basis of the World Health 
Organization (WHO) system (24). Tumors were subdivided into three histopathological 
groups: WHO Type I, keratinizing squamous cell carcinoma; WHO Type II, 
differentiated non-keratinizing carcinoma; and WHO Type III, undifferentiated 
carcinoma. The clinical staging of NPC was evaluated based on the TNM classification 
of the Union Internationale Contre le Cancer (UICC) (25). 
     Immunohistochemical Analysis. Consecutive 4 μm sections were cut from 
each block. Immunohistochemical staining was performed as previously described (5, 6, 
26). The following antibodies were used as primary antibodies: rabbit RAGE polyclonal 
antibody from Santa Cruz Biotechnology (Santa Cruz, CA); mouse LMP1 monoclonal 
antibody, rabbit S100 polyclonal antibody, and rabbit von Willebrand factor (vWF) 
antibody were from DAKO (Glostrup, Denmark). The sections were color-developed 
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with substrate/chromogen diaminobenzidine (DAKO, Copenhagen, Denmark). The 
sections were counterstained with methyl green. NPC specimens that had been used in 
previous studies, lingual carcinoma specimens, and malignant melanoma specimens 
were used as positive controls for LMP1 (6, 26), RAGE, and S100 proteins, respectively. 
The specificity of staining was confirmed using non-immune serum instead of the 
primary antibody as a negative control. 
     Evaluation of Immunohistochemical Staining for RAGE, LMP1, and S100 
proteins. The stained sections were independently examined by two of the authors (A.T. 
and N.W.). In each case, two arbitrary separate microscopic fields (x 200) containing > 
200 tumor cells were evaluated. After counting both immunoreactive cells and the total 
number of tumor cells, the average percentages of immunoreactive cells were calculated 
without knowledge of the clinical data.  
     The results for each protein were classified into three scores depending on the 
percentage of immunoreactive tumor cells: for RAGE protein, expression score 0, < 
20%; expression score 1, 20 to 50%; expression score 2, > 50%; for LMP1 protein, 
expression score 0, < 10%; expression score 1, 10 to 50%; expression score 2,  > 50%; 
and for S100 protein, expression score 0, < 30%; expression score 1, 30 to 60%; 
expression score 2, > 60%.  
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     Also, the results for each protein were classified into two subgroups depending on 
the percentage of immunoreactive tumor cells: for RAGE protein, < 20% (score 0) and 
≥20% (score 1,2) (18); for LMP1 protein, < 10% (score 0) and ≥10% (score 1,2) (27); 
and for S100 protein, < 30% (score 0) and ≥ 30% (score 1,2) (28); respectively. 
     Microvessel Counting. All microvessels were highlighted by staining endothelial 
cells with anti-vWF antibody. The area of most intense neovascularization was found by 
light microscopy in x 10 field followed by counting in x 400 field. Any endothelial cell 
or endothelial cluster staining positive for vWF that was clearly separate from adjacent 
microvessels was considered to be a single, countable vessel. Results were expressed as 
the highest number of microvessels identified within any single x 400 fields.  
     Plasmids, Cell Line, and Transient Transfection. A pcDNA3-based LMP1 
expression plasmid (pcLMP1) has been described previously (7). RAGE promoter 
luciferase chimeras (pGL-1, -5, -6, -7, and -5 NF-κB2m) were a kind gift from Dr. 
Hiroshi Yamamoto (Department of Biochemistry, Kanazawa University School of 
Medicine, Ishikawa, Japan) (29). Ad-AH cells, kindly provided by Dr. Erik K. 
Flemington (Tulane University, LA), are an EBV-negative human nasopharyngeal 
epithelial cell line (30). Ad-AH cells were maintained in Dulbecco's modified Eagle's 
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medium (DMEM) with 10% FBS and penicillin and streptomycin. For Western blot 
analysis, cells were transfected with 1 μg of the appropriate plasmids using the 
Effectene transfection kit (QIAGEN, Tokyo, Japan) in accordance with the 
manufacturer’s instructions. For luciferase reporter assay, cells were transfected with 
0.5 μg of the appropriate plasmids with or without 0.001 μg of pcLMP1. Forty-eight 
hours after transfection, Ad-AH cells were held for 24 h in DMEM with neither FBS 
nor antibiotics and with or without treatment with 50 ng/ml phorbol 12-myristate 
13-acetate (PMA) (Sigma, MO). 
     Western Blot Analysis for RAGE, LMP1, and S100 proteins. Whole cell 
lysates were extracted in 100 µl of RIPA buffer [50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 2 mM EDTA, 1% Nonidet P-40, 0.5% Na deoxycholate, 0.1% sodium dodecyl 
sulfate (SDS), 25 mM dithiothreitol, 0.2 mM Na orthovanadate, 100 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride], and protein concentration was determined by a Bio-Rad 
protein assay. Each cell lysate (100 μg) was solubilized for 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes 
(Amersham, Buckinghamshire, UK) by ATTO semidry transfer apparatus. The 
membranes were incubated with an antibody to RAGE, LMP1, or S100 protein at 4 
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overnight. Primary antibodies for each protein were the same as for 
immunohistochemistry. After incubation with horseradish peroxidase-conjugated 
secondary antibody (Santa Cruz Biotechnology, CA) for 60 min, reactive bands were 
visualized using the Super Signal West Pico Chemiluminescent Substrate (PIERCE, IL). 
To verify equal protein loading, the α-tubulin level in each lane was examined with the 
antibody to α-tubulin (Santa Cruz Biotechnology, CA). 
      Luciferase Reporter Assay. Luciferase reporter assays were performed with 
extracts of Ad-AH cells after transient transfection. Cells were incubated for 48 h after 
transfection and then harvested. Transfection efficiency was monitored by 
cotransfection with β-galactosidase reporter plasmid. Luciferase activities were 
measured using a Dual-LuciferaseTM reporter assay system (Promega, Tokyo, Japan) 
according to the manufacturer’s protocol with a luminometer (Labsystems, Helsinki, 
Finland).   
     Statistical Analysis. Data were analyzed using SPSS for Windows software 
version 11.0.1. The microvessel counts and the expressions of RAGE, LMP1, and S100 
proteins in relation to the clinicopathological data were analyzed using the 
Mann-Whitney U test or Kruskal-Wallis rank test. Correlations among RAGE, LMP1, 
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and S100 proteins were analyzed with the chi-square test. The relationship between 
microvessel counts and each protein expression was analyzed with the Mann-Whitney 
U test. P values of < 0.05 were considered significant. 
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RESULTS 
     Expressions of RAGE, LMP1, and S100 proteins in NPC tissues. RAGE 
protein was immunolocalized on the cell membrane and cytoplasm of tumor cells (Fig. 
1A), consistent with other tumors (18, 20, 21). LMP1 protein was also detected on the 
membrane and cytoplasm of tumor cells (Fig. 1B). The expression of RAGE and LMP1 
was usually high or low in parallel in the same case. Case I (Fig. 1A, B) shows a 
representative result in which both RAGE and LMP1 are highly expressed (score 2) in 
tumor cells. Surrounding normal cells were negative for both LMP1 and RAGE. In 
contrast, case II (Fig. 1C, D) is a representative result when RAGE and LMP1 
expressions were low (score 0). It was previously reported that 60 % of the primary site 
and 100 % of metastatic NPC showed S100 protein-positive cells (28), which suggests 
the constitutive existence of S100 protein as a ligand for RAGE in NPC. Thus, we 
performed immunohistochemical study for S100 protein in NPC tissues. S100 protein 
was observed mainly in the cytoplasm, and also occasionally in the nucleus of tumor 
cells with diffuse distribution in tumor cell nests (Fig. 1E). Most microvessels 
highlighted by staining vWF were localized at the tumor stroma. In WHO Type II, 
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microvessels were localized at the tumor stroma encircling each tumor cell nest. In 
WHO Type III, microvessels were detected as scattered in tumor cell nests (Fig. 1F).   
     Microvessel counts and the expression of each protein in relation to the 
progression of N factor were analyzed using the Mann-Whitney U test (Table 1). The N 
classification was subdivided into two categories (N0 and N1-3), according to the 
methods used in our previous studies (5). Detailed results showing the expressions of 
each protein and microvessel counts in relation to the clinicopathological data are 
summarized in supplementary Table 1’ online. In 33 cases of the lymph node 
metastasis-positive category (N1-3), the mean RAGE expression score was significantly 
higher than in nine cases of the lymph node metastasis-negative category (N0) (P = 
0.0005). In addition, in cases of positive lymph node metastasis (N1-3), the mean 
LMP1expression score was significantly higher than in the lymph node 
metastasis-negative category (N0) (P = 0.0484). There was no statistical difference in 
the mean expression score of S100 protein between the lymph node metastasis-positive 
category and the lymph node metastasis-negative category. These results suggest that 
both RAGE and LMP1 proteins are closely associated with lymph node metastasis in 
NPC, but S100 protein is not. In addition to each protein expression, we analyzed the 
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relationship between the results of microvessel counting and the progression of N factor. 
In cases of positive lymph node metastasis, microvessel counts were significantly 
higher than in the lymph node metastasis-negative category, compatible with our 
previous reports (6, 26).   
     Associations between LMP1, RAGE, and S100 protein expressions are 
summarized in Table 2. The expression of RAGE protein is significantly associated with 
the expression of LMP1 protein (P = 0.0093); however, there is no significant 
association between LMP1 and S100 proteins, or RAGE and S100 proteins.  
     The relationships between each protein expression and microvessel count are 
summarized in Table 3. As shown in our previous report, cases of 
LMP1-immunoreactivetumor cells ≥ 10% showed a significantly higher number of 
microvessel counts compared to cases of < 10% (P < 0.0001), which reconfirmed the 
importance of LMP1 in tumor neovascularization in NPC (6). Cases of 
RAGE-immunoreactive tumor cells ≥ 20% had significantly higher microvessel counts 
than cases with < 20% (P = 0.0020), which suggests the important role of RAGE 
protein in angiogenesis in NPC.         
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     Induction of RAGE by LMP1. The data obtained from immunohistochemical 
studies showed that all cases of high LMP1-immunoreactivity (≥ 10%) were also high 
in RAGE immunoreactivity (≥ 20%), in contrast to the 13 high RAGE 
immunoreactivity of 31 cases with low LMP1 immunoreactivity (< 10%) (Table 2), 
which suggests the expression of RAGE protein is significantly associated with the 
expression of LMP1 protein (P = 0.0093); therefore, we investigated whether LMP1 
protein could induce RAGE protein production in vitro. Ad-AH cells, an EBV-negative 
nasopharyngeal epithelial cell line, were transiently transfected with pcLMP1. RAGE 
protein was detected by Western blotting of cell extracts. As demonstrated in Figure 2, 
trace amounts of RAGE protein were detected in cells transfected with pcDNA3, a 
control plasmid; however, LMP1 induced the expression of RAGE protein, depending 
on the amount of transfected LMP1 expression plasmid. RAGE protein was also 
upregulated in cells incubated with PMA, which was used as a positive control. On the 
other hand, trace amounts of S100 protein were not affected either by transfection of 
LMP1 or incubation with PMA. To verify the equal protein loading, the α-tubulin level 
in each lane was examined. As expected from immunohistochemical study, results from 
Western blotting indicate that LMP1 induces the expression of RAGE protein, but not 
S100 protein, in Ad-AH cells.  
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     Transactivation of RAGE Promoter by LMP1. To confirm whether LMP1 
induces RAGE gene transcription and, if so, to delimit the regions involved in such 
transcriptional activations, a series of chimeric 5'-deletion promoter-luciferase reporter 
constructs were prepared (Fig. 3A). Ad-AH cells were transiently transfected with the 
constructs, and the effects of co-transfection of pcLMP1 on luciferase activity were 
determined. When pGL-1 or pGL-5-transfected cells were co-transfected with pcLMP1, 
promoter activities increased significantly (more than 5-fold) compared with those 
without pcLMP1. These results suggest that Sp-1 (-1628), AP-1 (-1542), NF-κB (-1542), 
Ets-1 (-1183) binding sites are not essential for the transcriptional activation of RAGE 
promoter; however, when cells were cotransfected with pGL-6 or pGL-7, luciferase 
activities were abolished (Fig. 3B). These results suggest that the element including the 
NF-κB binding site (-671) in the RAGE promoter is essential for the response to 
stimulation by LMP1. To determine the role of the NF-κB binding site (-671) in LMP1 
activation of the RAGE promoter, site-directed mutagenesis was performed at that site 
(pGL-5 NF-κB2m). When luciferase activities were assayed in cells transfected with the 
mutant, the inducibility by pcLMP1 was totally abolished (Fig. 3C). These results 




     In addition to its central role in transformation of cells by EBV, LMP1 is able to 
directly induce a comprehensive set of factors that promote tumor invasion and 
angiogenesis, which results in the increased metastatic potential of EBV-related 
malignancies including NPC (31). In the present study, the expression of LMP1 was 
significantly associated with microvessel counts and the progression of N factor in NPC, 
concordant with our previous report (6). In addition, we showed that the expression of 
LMP1 was correlated with the expression of RAGE protein. Although the number of 
NPC samples examined in this study was not sufficient to allow definite conclusions, 
this result prompted us to investigate whether LMP1 induces RAGE protein in 
nasopharyngeal epithelial cells. First, transient transfection revealed that LMP1 induced 
RAGE protein in Ad-AH cells. A luciferase reporter assay using various chimeric 
luciferase plasmids then revealed that the NF-κB-binding site (-671) in the RAGE 
promoter was essential to transactivate the RAGE promoter by LMP1. We didn’t 
confirm that LMP1-induced NF-κB could bind to the putative NF-κB site in the RAGE 
promoter. However, these results of luciferase reporter assay indicate that LMP1 
directly induces the expression of RAGE through transcriptional activation of the 
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RAGE promoter. Sp-1 (-1628), AP-1 (-1542), NF-κB (-1519), and Ets-1 (-1183) binding 
sites in pGL-1 luciferase reporter plasmid have only a limited effect on the 
transactivation of RAGE promoter, because truncation of these elements only partially 
affects the luciferase reporter activity induced by LMP1. As previously reported, LMP1 
transactivates MMP9 production through the activation of NF-κB and AP-1 signaling 
pathways (7). We have also reported that LMP1 promotes cell migration and invasive 
growth via Ets-1 expression in human epithelial cells (9). These results suggest that the 
essential binding sites for transactivation of the promoter by LMP1 are, at least in part, 
gene-specific in epithelial cells.    
     A close relationship between angiogenesis and lymph node metastasis has been 
demonstrated in malignant tumors (32, 33). As we previously reported, angiogenesis is 
strongly correlated with lymph node metastasis also in NPC (6, 26). Although the 
angiogenic role of RAGE remains somewhat controversial, several studies report that 
activated RAGE can promote aspects of angiogenic processes in vitro, including 
stimulation of endothelial cell proliferation and tube formation (34). To examine the 
role of RAGE protein in angiogenesis in NPC, we analyzed the correlation between the 
level of RAGE protein expression and microvessel counts in NPC tissues. As expected, 
the expression of RAGE was clearly correlated with the microvessel counts and 
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significantly associated with the progression of N factor. Furthermore, microvessel 
counts were correlated with the progression of N factor. These results suggest that 
LMP1-induced RAGE stimulates lymph node metastasis through the induction of 
angiogenesis in NPC, although the mechanism of RAGE-associated angiogenesis is 
unknown. VEGF plays an important role in lymph node metastasis through the 
induction of angiogenesis in NPC (6, 26). LMP1 directly induces VEGF 
transcriptionally through the activation of HIF-1 (12). LMP1 is involved in VEGF 
production indirectly through the induction of COX2 (11). It has been reported that 
RAGE can elicit angiogenesis through the induction of VEGF, thereby playing an active 
part in the development and progression of diabetic microangiopathies (14, 34), in 
which activated RAGE induces VEGF expression transcriptionally through the 
activation of NF-κB, AP-1, and HIF-1 (35). Although we did not examine the 
expression of VEGF in this study, these reports support the hypothesis that 
LMP1-induced RAGE induces angiogenesis, at least in part, through the induction of 
VEGF in NPC. Thus, LMP1-induced RAGE can be a novel key regulator to stimulate 
VEGF expression in NPC.  
     The importance of lymphangiogenesis induced by tumor-secreted cytokines has 
been demonstrated recently (36). VEGF-C and VEGF-D expression in tumor cells has 
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been linked to lymphangiogenesis associated with tumor invasion into lymphatic 
vessels, and lymph node metastasis. Sasahira et al. examined the role of RAGE for 
lymphangiogenesis in human oral squamous cell carcinoma (SCC) (19). They showed 
that RAGE protein concentration in tumor tissues was not correlated with VEGF-C 
concentration, lymph vessel counts or nodal metastasis in oral SCC. Although the 
induction of VEGF-C by LMP1-induced RAGE may be controversial in NPC as well as 
in oral SCC, the direct induction of VEGF-C by LMP1 should be examined, because 
VEGF-C induction is a result of NF-κB or p38-MAPK, both of which are involved in 
the downstream signaling pathway of LMP1 (37).              
     Recently, Taguchi et al. reported that RAGE was closely associated with cell 
growth and invasion through MAPK activation, and matrix metalloproteinase (MMP) 
2/9 induction in glioma cells (16). In pancreatic cancer cells, RAGE and MMP9 are 
expressed concordant with the metastatic ability of human pancreatic cancer cells both 
at protein and mRNA levels (38). Kuniyasu et al. reported that RAGE antisense 
S-oligodeoxynucleotide treatment suppressed the invasive activity of RAGE-positive 
gastric carcinoma cells by inhibiting the ability to degrade type IV collagen, as 
estimated by in vitro invasion assay (18). These reports suggest that RAGE induces the 
invasiveness of tumor cells, especially through the upregulation of type IV collagenase 
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activity. Although the importance of RAGE-induced MMP9 in the invasiveness of 
cancer cells is well established, MMP9-derived invasiveness indirectly stimulated by 
LMP1-induced RAGE should be limited or only partial, because LMP1 is a strong 
direct transcriptional inducer of MMP9 (7). 
     It has already been reported that S100 protein is constitutively expressed and 
detected in NPC tumor cells (28). Thus, we tested only the expression of S100 protein 
as a ligand of RAGE in this study. In the future, the present study should be expanded to 
examine the role of enhanced interaction of LMP1-induced RAGE with its other ligands, 
AGE or EN-RAGE, members of the S100/calgranulin family, which also affects RAGE 
activation.  
     Finally, we reported here that EBV-LMP1 induces the expression of RAGE 
protein, which is suggested to play a key role in angiogenesis in NPC, in addition to 
factors such as COX2 and HIF-1. This report shows additional evidence that inhibition 
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Fig. 1. Immunohistochemical detection of RAGE (A and C), LMP1 (B and D), S100 (E), 
and von Willebrand factor (F) in NPC biopsy tissues. Case I (A and B) shows 
representative results with high RAGE and LMP1 expression (score 2) in consecutive 
sections. Case II (C and D) shows the representative result with low expressions (score 
0) of RAGE and LMP1. Original magnification, x 400.  
 
Fig. 2. LMP1 induces the expression of RAGE in Ad-AH cells. Lysates of Ad-AH cells 
transfected with pcDNA3 with or without pcLMP1 are loaded on to corresponding lanes, 
and examined by Western blotting with antibodies to RAGE, S100, LMP1, or α-tubulin 
proteins, as described in Materials and Methods. Two different amounts of LMP1 
expression plasmid were transiently transfected. Ad-AH cells treated with PMA (50 
ng/ml) were used as a positive control for RAGE induction. α-tubulin was used as a 
loading control. PMA, phorbol 12-myristate 13-acetate. 
 
Fig. 3. (A) Schematic constructions of RAGE promoter luciferase chimeras. The RAGE 
promoter has four Sp-1 binding sites, one Ap-1 binding site, three NF-κB binding sites, 
and one Ets-1 binding site. pGL-5 NF-κB2m contained the region -751 to +43, but with 
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the mutation in an NF-κB site (-671). (B) In cells transfected with pGL-1 and pGL-5, 
promoter activities increased significantly by LMP1. On the other hand, in cells 
transfected with pGL-6 and pGL-7, promoter activities were the same as controls. The 
results of triplicate experiments are shown. (C) Determination of responsive elements in 
the promoter of RAGE. pGL-5 or pGL-5 NF-κB2m was transiently cotransfected with 
pcLMP1 into Ad-AH cells. pcDNA3 was used as a control vector. Luciferase activities 
transfected wih the mutant are significantly lower than those with pGL-5. The results of 
triplicate experiments are shown. 
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